Incidence of subclinical ketosis in cows supplemented with a monensin controlled-release capsule in Holstein cattle, Florida, USA

The objective of this study was to determine the effect of a monensin controlled-release capsule on the proportion of cows with subclinical ketosis (SK). During July to August 2001, 300 cows dried-off 50–70 days before expected parturition were randomly assigned to either a treatment (n = 150, oral capsule, 335 mg/d of monesin for 95 d) or control group (no capsule, n = 150). At 14 days postpartum, a milk sample was obtained and evaluated for β-hydroxybutyrate (BHBA) using a semi-quantitative ketone test strip. In a sub-sample of 50 cows per group a blood sample was taken and analyzed for BHBA using an ELISA kit. Milk BHBA ≥200 μmol/L was used as the cut-off value for diagnosis of SK. The incidence of SK based on the milk test was statistically different between groups (P ≤ 0.05) with a value of 26.6% for control and 14.5% for cows treated with monensin, respectively. Cows treated with monensin were 0.68 times less likely to give a positive result for milk BHBA than non-treated cows (0.53–0.80; 95% CI). Serum BHBA concentrations did not differ between groups (0.81 ± 0.09 mmol/L versus 0.70 ± 0.07 mmol/L for controls and treated, respectively; P > 0.05). However, for each incremental increase in serum BHBA of 0.1 mmol/L occurrence of SK increased 52% (OR = 1.52; 1.21–1.91; 95% CI).